Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review [PDF]
Frontiers in MedicineBackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable
Xiaofang Zhang +7 more
doaj +5 more sources
Tofacitinib for Pityriasis Rubra Pilaris: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyHongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Tan H +5 more
doaj +5 more sources
Juvenile Pityriasis Rubra Pilaris [PDF]
Dermatology Practical & Conceptual, 2023 Yihang Xie +3 more
doaj +4 more sources
Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report [PDF]
SAGE Open Medical Case Reports, 2023 Pityriasis rubra pilaris is a rare inflammatory dermatosis characterized by orange-red confluent plaques, hyperkeratotic follicular papules, palmoplantar keratoderma, and, in some cases, erythroderma.
Mysa Saad, Alison Spurr, Jennifer Lipson
doaj +2 more sources
Drug-related pityriasis rubra pilaris with acantholysis [PDF]
Vojnosanitetski Pregled, 2013 Introduction. Acantholysis is rarely reported histological feature of Pityriasis rubra pilaris (PRP), recently recognized as having diagnostic specificity for differentiating PRP from psoriasis. Case report.
Gajinov Zorica T. +5 more
doaj +3 more sources
Refractory pityriasis rubra pilaris treated with abrocitinib [PDF]
Dermatology ReportsPityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts the quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor
Filip Rob
doaj +2 more sources
Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report [PDF]
Clinical Case ReportsPityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential
Mahsa Taremi, Nikoo Mozafari
doaj +2 more sources
A case of pityriasis rubra pilaris secondary to ponatinib [PDF]
SAGE Open Medical Case ReportsPonatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting ...
Ariana Nateghi +2 more
doaj +2 more sources
Targeting IL-1 controls refractory pityriasis rubra pilaris. [PDF]
Sci AdvPityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis ...
Schmauch E +22 more
europepmc +3 more sources
Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient [PDF]
Clinical, Cosmetic and Investigational DermatologyVito Di Lernia, Francesca Peccerillo Dermatology Unit, Azienda Unità Sanitaria Locale- IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence: Vito Di Lernia, Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Viale ...
Di Lernia V, Peccerillo F
doaj +2 more sources